Skip to main content
Erschienen in: Current Diabetes Reports 11/2018

01.11.2018 | Diabetes Epidemiology (E Selvin and K Foti, Section Editors)

Issues in Defining the Burden of Prediabetes Globally

verfasst von: Justin B. Echouffo-Tcheugui, Andre P. Kengne, Mohammed K. Ali

Erschienen in: Current Diabetes Reports | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Using a global perspective, this review collates evidence on the heterogeneity of prediabetes definitions and diagnostic methods, their clinical and public health implications, and discusses possible options for improvement.

Recent Findings

Our review notes that the concept of prediabetes is increasingly recognized worldwide, but against a background of non-uniform definition and diagnostic criteria. This results in widely varying burden estimation.

Summary

Current evidence shows a variety of prediabetes phenotypes. This reflects biological and diagnostic heterogeneity, resulting from the use of different tests (glucose or HbA1C) and thresholds to define prediabetes. The biological and diagnostic variabilities have implications for the characterization of the burden of prediabetes, natural history, prognosis, screening, implementation of lifestyle or drug interventions to mitigate related health risks, and monitoring of the effects of such interventions.
Literatur
1.
Zurück zum Zitat Herron CA. Screening in diabetes mellitus: report of the Atlanta workshop. Diabetes Care. 1979;2:357–62.CrossRef Herron CA. Screening in diabetes mellitus: report of the Atlanta workshop. Diabetes Care. 1979;2:357–62.CrossRef
2.
Zurück zum Zitat Fajans SS. I. Identification of chemical diabetes. The definition of chemical diabetes. Metabolism. 1973;22:211–7.CrossRef Fajans SS. I. Identification of chemical diabetes. The definition of chemical diabetes. Metabolism. 1973;22:211–7.CrossRef
3.
Zurück zum Zitat Jackson WP. Prediabetes; a synthesis. Postgrad Med J. 1959;35:287–96.CrossRef Jackson WP. Prediabetes; a synthesis. Postgrad Med J. 1959;35:287–96.CrossRef
4.
Zurück zum Zitat World Health Organization. WHO Expert Committee on Diabetes Mellitus. A report of the WHO Expert Committee. Geneva; 1965. World Health Organization. WHO Expert Committee on Diabetes Mellitus. A report of the WHO Expert Committee. Geneva; 1965.
5.
Zurück zum Zitat Group NDD. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979;28:1039–57.CrossRef Group NDD. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979;28:1039–57.CrossRef
6.
Zurück zum Zitat Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–97. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–97.
7.
Zurück zum Zitat World Health Organization. WHO Expert Committee on Diabetes Mellitus. Geneva; 1980. World Health Organization. WHO Expert Committee on Diabetes Mellitus. Geneva; 1980.
8.
Zurück zum Zitat Mellitus D. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1 : Diagnosis and Classification of. World Health. 1999;15:539–53. Mellitus D. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1 : Diagnosis and Classification of. World Health. 1999;15:539–53.
9.
Zurück zum Zitat Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population: Paris prospective study. Diabetes. 1991;40:796–799.CrossRef Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population: Paris prospective study. Diabetes. 1991;40:796–799.CrossRef
10.
Zurück zum Zitat Genuth S, KGMM A, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.CrossRef Genuth S, KGMM A, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–7.CrossRef
11.
Zurück zum Zitat Narayan KMV, Imperatore G, Benjamin SM, Engelgau MM. Targeting people with pre-diabetes. BMJ. 2002;325:403–4.CrossRef Narayan KMV, Imperatore G, Benjamin SM, Engelgau MM. Targeting people with pre-diabetes. BMJ. 2002;325:403–4.CrossRef
12.
Zurück zum Zitat Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, et al. The prevention or delay of type 2 diabetes. Diabetes Care. 2003;26(Suppl 1):S62–9.PubMed Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, et al. The prevention or delay of type 2 diabetes. Diabetes Care. 2003;26(Suppl 1):S62–9.PubMed
13.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010;33:S11–61. American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010;33:S11–61.
14.
Zurück zum Zitat World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate. Geneva; 2006. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate. Geneva; 2006.
15.
Zurück zum Zitat Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, et al. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1–8.CrossRef Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, et al. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1–8.CrossRef
16.
Zurück zum Zitat Qiao Q. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61–9.CrossRef Qiao Q. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61–9.CrossRef
17.
Zurück zum Zitat James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, et al. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care. 2011;34:387–91.CrossRef James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, et al. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care. 2011;34:387–91.CrossRef
18.
Zurück zum Zitat Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care. 2000;23:1108–12.CrossRef Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care. 2000;23:1108–12.CrossRef
19.
Zurück zum Zitat Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353:1454–62.CrossRef Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353:1454–62.CrossRef
20.
Zurück zum Zitat Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–11.CrossRef Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–11.CrossRef
21.
Zurück zum Zitat Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.CrossRef Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.CrossRef
22.
Zurück zum Zitat Lorenzo C, Wagenknecht LE, Hanley AJG, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010;33:2104–9.CrossRef Lorenzo C, Wagenknecht LE, Hanley AJG, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010;33:2104–9.CrossRef
23.
Zurück zum Zitat • Færch K, Johansen NB, Witte DR, Lauritzen T, Jørgensen ME, Vistisen D. Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. J Clin Endocrinol Metab. 2015;100:707–16. This study addressed the extent to which metabolic abnormalities (insulin resistance and beta-cell dysfunction) are captured by a glycated hemoglobin-based definition of prediabetes. CrossRef • Færch K, Johansen NB, Witte DR, Lauritzen T, Jørgensen ME, Vistisen D. Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. J Clin Endocrinol Metab. 2015;100:707–16. This study addressed the extent to which metabolic abnormalities (insulin resistance and beta-cell dysfunction) are captured by a glycated hemoglobin-based definition of prediabetes. CrossRef
24.
Zurück zum Zitat Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105–16.CrossRef Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105–16.CrossRef
25.
Zurück zum Zitat Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44:991–1005.CrossRef Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44:991–1005.CrossRef
26.
Zurück zum Zitat Wheeler E, Leong A, Liu C-T, Hivert M-F, Strawbridge RJ, Podmore C, et al. Impact of common genetic determinants of hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: a transethnic genome-wide meta-analysis. PLoS Med. 2017;14:e1002383.CrossRef Wheeler E, Leong A, Liu C-T, Hivert M-F, Strawbridge RJ, Podmore C, et al. Impact of common genetic determinants of hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: a transethnic genome-wide meta-analysis. PLoS Med. 2017;14:e1002383.CrossRef
27.
Zurück zum Zitat • Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. This study reports the most recent estimates of the prevalence of prediabetes in various regions of the world. CrossRef • Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. This study reports the most recent estimates of the prevalence of prediabetes in various regions of the world. CrossRef
28.
Zurück zum Zitat Anjana RM, CSS R, Deepa M, Pradeepa R, Sudha V, Nair HD, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai urban rural epidemiology study (CURES). Diabetes Care. 2015;38:1441–8.CrossRef Anjana RM, CSS R, Deepa M, Pradeepa R, Sudha V, Nair HD, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai urban rural epidemiology study (CURES). Diabetes Care. 2015;38:1441–8.CrossRef
29.
Zurück zum Zitat Qiao Q. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care. 2003;26:1770–80.CrossRef Qiao Q. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care. 2003;26:1770–80.CrossRef
30.
Zurück zum Zitat • Shen J, Kondal D, Rubinstein A, Irazola V, Gutierrez L, Miranda JJ, et al. A Multiethnic study of pre-diabetes and diabetes in LMIC. Glob Heart. 2016;11:61–70. This study reports the global prevalence of prediabetes, including estimates of prevalence of prediabetes in various regions of the world. CrossRef • Shen J, Kondal D, Rubinstein A, Irazola V, Gutierrez L, Miranda JJ, et al. A Multiethnic study of pre-diabetes and diabetes in LMIC. Glob Heart. 2016;11:61–70. This study reports the global prevalence of prediabetes, including estimates of prevalence of prediabetes in various regions of the world. CrossRef
31.
Zurück zum Zitat Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988–2012. JAMA. 2015;314:1021–9.CrossRef Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988–2012. JAMA. 2015;314:1021–9.CrossRef
32.
Zurück zum Zitat Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948.CrossRef Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948.CrossRef
33.
Zurück zum Zitat Menke A, Casagrande S, Cowie CC. Prevalence of diabetes in adolescents aged 12 to 19 years in the United States, 2005–2014. JAMA. 2016;316:344.CrossRef Menke A, Casagrande S, Cowie CC. Prevalence of diabetes in adolescents aged 12 to 19 years in the United States, 2005–2014. JAMA. 2016;316:344.CrossRef
34.
Zurück zum Zitat Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med. 2014;160:517.CrossRef Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med. 2014;160:517.CrossRef
35.
Zurück zum Zitat Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW, Geiss LS, et al. Secular Changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose. Diabetes Care. 2013;36:2286–93.CrossRef Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW, Geiss LS, et al. Secular Changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose. Diabetes Care. 2013;36:2286–93.CrossRef
36.
Zurück zum Zitat Caspersen CJ, Thomas GD, Beckles GLA, Bullard KMK. Secular changes in prediabetes indicators among older-adult americans, 1999–2010. Am J Prev Med. 2015;48:253–63.CrossRef Caspersen CJ, Thomas GD, Beckles GLA, Bullard KMK. Secular changes in prediabetes indicators among older-adult americans, 1999–2010. Am J Prev Med. 2015;48:253–63.CrossRef
37.
Zurück zum Zitat Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40.CrossRef Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40.CrossRef
38.
Zurück zum Zitat NCD Risk Factor Collaboration (NCD-RisC). Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. Lancet Diabetes Endocrinol. 2015;3:624–37.CrossRef NCD Risk Factor Collaboration (NCD-RisC). Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. Lancet Diabetes Endocrinol. 2015;3:624–37.CrossRef
39.
Zurück zum Zitat Barr RG, Nathan DM, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med. 2002;137:263–72.CrossRef Barr RG, Nathan DM, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med. 2002;137:263–72.CrossRef
40.
Zurück zum Zitat Balion CM, Raina PS, Gerstein HC, Santaguida PL, Morrison KM, Booker L, et al. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clin Chem Lab Med. 2007;45:1180–5.CrossRef Balion CM, Raina PS, Gerstein HC, Santaguida PL, Morrison KM, Booker L, et al. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clin Chem Lab Med. 2007;45:1180–5.CrossRef
41.
Zurück zum Zitat Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess. 2005;1–11. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess. 2005;1–11.
42.
Zurück zum Zitat Selvin E, Wang D, Lee AK, Bergenstal RM, Coresh J. Identifying trends in undiagnosed diabetes in U.S. Adults by using a confirmatory definition: a cross-sectional study. Ann Intern Med. 2017;167:769–76.CrossRef Selvin E, Wang D, Lee AK, Bergenstal RM, Coresh J. Identifying trends in undiagnosed diabetes in U.S. Adults by using a confirmatory definition: a cross-sectional study. Ann Intern Med. 2017;167:769–76.CrossRef
43.
Zurück zum Zitat Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care. 2010;33:562–8.CrossRef Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care. 2010;33:562–8.CrossRef
44.
Zurück zum Zitat Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care. 2010;33:2190–5.CrossRef Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care. 2010;33:2190–5.CrossRef
45.
Zurück zum Zitat Menke A, Rust KF, Cowie CC. Diabetes based on 2-h plasma glucose among those classified as having prediabetes based on fasting plasma glucose or A1c. Diab Vasc Dis Res. 2018;15:46–54.CrossRef Menke A, Rust KF, Cowie CC. Diabetes based on 2-h plasma glucose among those classified as having prediabetes based on fasting plasma glucose or A1c. Diab Vasc Dis Res. 2018;15:46–54.CrossRef
46.
Zurück zum Zitat Faerch K, Hulmán A, Solomon TPJ. Heterogeneity of pre-diabetes and type 2 diabetes: implications for prediction, prevention and treatment responsiveness. Curr Diabetes Rev. 2016;12:30–41.CrossRef Faerch K, Hulmán A, Solomon TPJ. Heterogeneity of pre-diabetes and type 2 diabetes: implications for prediction, prevention and treatment responsiveness. Curr Diabetes Rev. 2016;12:30–41.CrossRef
47.
Zurück zum Zitat • Ali MK, Bullard KMK, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018;6:392–403. This study describes the cardiovascular and renal burdens associated with the various prediabetes phenotypes in a US national sample. CrossRef • Ali MK, Bullard KMK, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018;6:392–403. This study describes the cardiovascular and renal burdens associated with the various prediabetes phenotypes in a US national sample. CrossRef
48.
Zurück zum Zitat •• Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M, et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5:34–42. This study investigated the ability of all the existing definitions of prediabetes at accurately predicting a vast array of outcomes (cardiovascular, renal and mortality). CrossRef •• Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M, et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5:34–42. This study investigated the ability of all the existing definitions of prediabetes at accurately predicting a vast array of outcomes (cardiovascular, renal and mortality). CrossRef
49.
Zurück zum Zitat Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167:1545.CrossRef Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167:1545.CrossRef
51.
Zurück zum Zitat Lee LT, Alexandrov AW, Howard VJ, Kabagambe EK, Hess MA, McLain RM, et al. Race, regionality and pre-diabetes in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Prev Med. 2014;63:43–7.CrossRef Lee LT, Alexandrov AW, Howard VJ, Kabagambe EK, Hess MA, McLain RM, et al. Race, regionality and pre-diabetes in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Prev Med. 2014;63:43–7.CrossRef
52.
Zurück zum Zitat Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL, KM F, et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284.CrossRef Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL, KM F, et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284.CrossRef
53.
Zurück zum Zitat Williams DR, Priest N, Anderson NB. Understanding associations among race, socioeconomic status, and health: Patterns and prospects. Health Psychol. 2016;35:407–11.CrossRef Williams DR, Priest N, Anderson NB. Understanding associations among race, socioeconomic status, and health: Patterns and prospects. Health Psychol. 2016;35:407–11.CrossRef
54.
Zurück zum Zitat Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011;40:804–18.CrossRef Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011;40:804–18.CrossRef
55.
Zurück zum Zitat Agardh EE, Ahlbom A, Andersson T, Efendic S, Grill V, Hallqvist J, et al. Socio-economic position at three points in life in association with type 2 diabetes and impaired glucose tolerance in middle-aged Swedish men and women. Int J Epidemiol. 2007;36:84–92.CrossRef Agardh EE, Ahlbom A, Andersson T, Efendic S, Grill V, Hallqvist J, et al. Socio-economic position at three points in life in association with type 2 diabetes and impaired glucose tolerance in middle-aged Swedish men and women. Int J Epidemiol. 2007;36:84–92.CrossRef
56.
Zurück zum Zitat Derks IPM, Koster A, Schram MT, Stehouwer CDA, Dagnelie PC, Groffen DAI, et al. The association of early life socioeconomic conditions with prediabetes and type 2 diabetes: results from the Maastricht study. Int J Equity Health. 2017;16:61.CrossRef Derks IPM, Koster A, Schram MT, Stehouwer CDA, Dagnelie PC, Groffen DAI, et al. The association of early life socioeconomic conditions with prediabetes and type 2 diabetes: results from the Maastricht study. Int J Equity Health. 2017;16:61.CrossRef
57.
Zurück zum Zitat • Cavagnolli G, Pimentel AL, PAC F, Gross JL, Camargo JL. Effect of ethnicity on HbA1c levels in individuals without diabetes: systematic review and meta-analysis. PLoS One. 2017;12:e0171315. This study provides a systematic overview of the evidence on the relation between ethnicity and glycated hemoglobin levels. CrossRef • Cavagnolli G, Pimentel AL, PAC F, Gross JL, Camargo JL. Effect of ethnicity on HbA1c levels in individuals without diabetes: systematic review and meta-analysis. PLoS One. 2017;12:e0171315. This study provides a systematic overview of the evidence on the relation between ethnicity and glycated hemoglobin levels. CrossRef
58.
Zurück zum Zitat Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97:1067–72.CrossRef Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97:1067–72.CrossRef
59.
Zurück zum Zitat Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007;30:2453–7.CrossRef Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007;30:2453–7.CrossRef
60.
Zurück zum Zitat Herman WH, Dungan KM, Wolffenbuttel BHR, Buse JB, Fahrbach JL, Jiang H, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:1689–94.CrossRef Herman WH, Dungan KM, Wolffenbuttel BHR, Buse JB, Fahrbach JL, Jiang H, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:1689–94.CrossRef
61.
Zurück zum Zitat Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011;154:303–9.CrossRef Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011;154:303–9.CrossRef
62.
Zurück zum Zitat Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152:770–7.CrossRef Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152:770–7.CrossRef
63.
Zurück zum Zitat Chapp-Jumbo E, Edeoga C, Wan J, Dagogo-Jack S. Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Research Group. Ethnic disparity in hemoglobin A1c levels among normoglycemic offspring of parents with type 2 diabetes mellitus. Endocr Pract. 2012;18:356–62.CrossRef Chapp-Jumbo E, Edeoga C, Wan J, Dagogo-Jack S. Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Research Group. Ethnic disparity in hemoglobin A1c levels among normoglycemic offspring of parents with type 2 diabetes mellitus. Endocr Pract. 2012;18:356–62.CrossRef
64.
Zurück zum Zitat Shipman KE, Jawad M, Sullivan KM, Ford C, Gama R. Ethnic/racial determinants of glycemic markers in a UK sample. Acta Diabetol. 2015;52:687–92.CrossRef Shipman KE, Jawad M, Sullivan KM, Ford C, Gama R. Ethnic/racial determinants of glycemic markers in a UK sample. Acta Diabetol. 2015;52:687–92.CrossRef
65.
Zurück zum Zitat de Miranda VA, Cruz Filho RA, de Oliveira TS, Moscavitch SD, Kang HC, Miranda Chagas SV, et al. Racial differences in HbA1c: a cross-sectional analysis of a Brazilian public primary care population. Prim Care Diabetes. 2013;7:135–41.CrossRef de Miranda VA, Cruz Filho RA, de Oliveira TS, Moscavitch SD, Kang HC, Miranda Chagas SV, et al. Racial differences in HbA1c: a cross-sectional analysis of a Brazilian public primary care population. Prim Care Diabetes. 2013;7:135–41.CrossRef
66.
Zurück zum Zitat Mostafa SA, Davies MJ, Webb DR, Srinivasan BT, Gray LJ, Khunti K. Independent effect of ethnicity on glycemia in South Asians and White Europeans. Diabetes Care. 2012;35:1746–8.CrossRef Mostafa SA, Davies MJ, Webb DR, Srinivasan BT, Gray LJ, Khunti K. Independent effect of ethnicity on glycemia in South Asians and White Europeans. Diabetes Care. 2012;35:1746–8.CrossRef
67.
Zurück zum Zitat Jørgensen ME, Bjerregaard P, Borch-Johnsen K, Witte D. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab. 2010;95:E333–6.CrossRef Jørgensen ME, Bjerregaard P, Borch-Johnsen K, Witte D. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab. 2010;95:E333–6.CrossRef
68.
Zurück zum Zitat Selvin E. Are there clinical implications of racial differences in HbA1c? A difference, to be a difference, must make a difference. Diabetes Care. 2016;39:1462–7.CrossRef Selvin E. Are there clinical implications of racial differences in HbA1c? A difference, to be a difference, must make a difference. Diabetes Care. 2016;39:1462–7.CrossRef
69.
Zurück zum Zitat Herman WH. Are there clinical implications of racial differences in HbA1c? Yes, to not consider can do great harm! Diabetes Care. 2016;39:1458–61.CrossRef Herman WH. Are there clinical implications of racial differences in HbA1c? Yes, to not consider can do great harm! Diabetes Care. 2016;39:1458–61.CrossRef
70.
Zurück zum Zitat Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59:3229–39.CrossRef Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59:3229–39.CrossRef
71.
Zurück zum Zitat Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78:305–12.CrossRef Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78:305–12.CrossRef
72.
Zurück zum Zitat Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, KMK B, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33:1665–73.CrossRef Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, KMK B, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33:1665–73.CrossRef
73.
Zurück zum Zitat Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, et al. HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011;378:147–55.CrossRef Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, et al. HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011;378:147–55.CrossRef
74.
Zurück zum Zitat •• Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, et al. Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56:1489–93. This study gives an overview of studies of the rate progression to diabetes among individuals with prediabetes defined on the basis of glycated hemoglobin. CrossRef •• Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, et al. Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56:1489–93. This study gives an overview of studies of the rate progression to diabetes among individuals with prediabetes defined on the basis of glycated hemoglobin. CrossRef
75.
Zurück zum Zitat Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. Diabet Med. 2007;24:200–7.CrossRef Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. Diabet Med. 2007;24:200–7.CrossRef
76.
Zurück zum Zitat Færch K, Witte DR, Brunner EJ, Kivimäki M, Tabák A, Jørgensen ME, et al. Physical activity and improvement of glycemia in prediabetes by different diagnostic criteria. J Clin Endocrinol Metab. 2017;102:3712–21.CrossRef Færch K, Witte DR, Brunner EJ, Kivimäki M, Tabák A, Jørgensen ME, et al. Physical activity and improvement of glycemia in prediabetes by different diagnostic criteria. J Clin Endocrinol Metab. 2017;102:3712–21.CrossRef
77.
Zurück zum Zitat • Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953. This study is a good summary of the evidence on the influence of prediabetes on the risk of cardiovascular disease. CrossRef • Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953. This study is a good summary of the evidence on the influence of prediabetes on the risk of cardiovascular disease. CrossRef
78.
Zurück zum Zitat Juraschek SP, Steffes MW, Selvin E. Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. Clin Chem. 2012;58:1648–55.CrossRef Juraschek SP, Steffes MW, Selvin E. Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. Clin Chem. 2012;58:1648–55.CrossRef
79.
Zurück zum Zitat Kengne AP, Erasmus RT, Levitt NS, Matsha TE. Alternative indices of glucose homeostasis as biochemical diagnostic tests for abnormal glucose tolerance in an African setting. Prim Care Diabetes. 2017;11:119–31.CrossRef Kengne AP, Erasmus RT, Levitt NS, Matsha TE. Alternative indices of glucose homeostasis as biochemical diagnostic tests for abnormal glucose tolerance in an African setting. Prim Care Diabetes. 2017;11:119–31.CrossRef
80.
Zurück zum Zitat Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS, Steffes M, et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation. 2015;132:269–77.CrossRef Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS, Steffes M, et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation. 2015;132:269–77.CrossRef
81.
Zurück zum Zitat Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014;2:279–88.CrossRef Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014;2:279–88.CrossRef
82.
Zurück zum Zitat Parrinello CM, Sharrett AR, Maruthur NM, Bergenstal RM, Grams ME, Coresh J, et al. Racial differences in and prognostic value of biomarkers of hyperglycemia. Diabetes Care. 2016;39:589–95.CrossRef Parrinello CM, Sharrett AR, Maruthur NM, Bergenstal RM, Grams ME, Coresh J, et al. Racial differences in and prognostic value of biomarkers of hyperglycemia. Diabetes Care. 2016;39:589–95.CrossRef
83.
Zurück zum Zitat Selvin E, Warren B, He X, Sacks DB, Saenger AK. Establishment of community-based reference intervals for fructosamine, glycated albumin, and 1,5-anhydroglucitol. Clin Chem. 2018;64:843–50.CrossRef Selvin E, Warren B, He X, Sacks DB, Saenger AK. Establishment of community-based reference intervals for fructosamine, glycated albumin, and 1,5-anhydroglucitol. Clin Chem. 2018;64:843–50.CrossRef
84.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef
85.
Zurück zum Zitat Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.CrossRef Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.CrossRef
86.
Zurück zum Zitat Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783–9.CrossRef Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783–9.CrossRef
87.
Zurück zum Zitat Ramachandran AA, Diabetes I, Programme P, Snehalatha C, Mary S, Mukesh B, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.CrossRef Ramachandran AA, Diabetes I, Programme P, Snehalatha C, Mary S, Mukesh B, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.CrossRef
88.
Zurück zum Zitat Saito T, Watanabe M, Nishida J, Izumi T, Omura M, Takagi T, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171:1352–60.CrossRef Saito T, Watanabe M, Nishida J, Izumi T, Omura M, Takagi T, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171:1352–60.CrossRef
89.
Zurück zum Zitat Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.CrossRef Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.CrossRef
90.
Zurück zum Zitat The Diabetes Prevention Program Research Group*. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150–6. The Diabetes Prevention Program Research Group*. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150–6.
91.
Zurück zum Zitat Dream T, Assessment DR, Investigators T. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.CrossRef Dream T, Assessment DR, Investigators T. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.CrossRef
92.
Zurück zum Zitat De Fronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15.CrossRef De Fronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15.CrossRef
93.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRef
94.
Zurück zum Zitat Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.CrossRef Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.CrossRef
95.
Zurück zum Zitat Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, et al. Long-term sustainability of diabetes prevention approaches. JAMA. 2017;177:1808. Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, et al. Long-term sustainability of diabetes prevention approaches. JAMA. 2017;177:1808.
96.
Zurück zum Zitat Weber MB, Ranjani H, Staimez LR, Anjana RM, Ali MK, KMV N, et al. The stepwise approach to diabetes prevention: results from the D-CLIP randomized controlled trial. Diabetes Care. 2016;39:1760–7.CrossRef Weber MB, Ranjani H, Staimez LR, Anjana RM, Ali MK, KMV N, et al. The stepwise approach to diabetes prevention: results from the D-CLIP randomized controlled trial. Diabetes Care. 2016;39:1760–7.CrossRef
97.
Zurück zum Zitat Thankappan KR, Sathish T, Tapp RJ, Shaw JE, Lotfaliany M, Wolfe R, et al. A peer-support lifestyle intervention for preventing type 2 diabetes in India: a cluster-randomized controlled trial of the Kerala Diabetes Prevention Program. PLoS Med. 2018;15:e1002575.CrossRef Thankappan KR, Sathish T, Tapp RJ, Shaw JE, Lotfaliany M, Wolfe R, et al. A peer-support lifestyle intervention for preventing type 2 diabetes in India: a cluster-randomized controlled trial of the Kerala Diabetes Prevention Program. PLoS Med. 2018;15:e1002575.CrossRef
98.
Zurück zum Zitat Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KMV, Ali MK. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care. 2018;41:1526–34.CrossRef Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KMV, Ali MK. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care. 2018;41:1526–34.CrossRef
Metadaten
Titel
Issues in Defining the Burden of Prediabetes Globally
verfasst von
Justin B. Echouffo-Tcheugui
Andre P. Kengne
Mohammed K. Ali
Publikationsdatum
01.11.2018
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 11/2018
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-018-1089-y

Weitere Artikel der Ausgabe 11/2018

Current Diabetes Reports 11/2018 Zur Ausgabe

Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)

Beyond Statins: Who and When to Prescribe?

Pathogenesis of Type 1 Diabetes (A Pugliese and SJ Richardson, Section Editors)

The Impact of Pancreatic Beta Cell Heterogeneity on Type 1 Diabetes Pathogenesis

Other Forms of Diabetes and Its Complications (JJ Nolan and H Thabit, Section Editors)

Diabetes and HIV

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Vegetarian Diets and the Risk of Diabetes

Health Care Delivery Systems and Implementation in Diabetes (ME McDonnell and AR Sadhu, Section Editors)

App-Based Insulin Calculators: Current and Future State

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.